| Fund ID | 805-7328857121 |
| Fund type | Private Equity Fund |
| 3(c)(1) exclusion | No |
| 3(c)(7) exclusion | Yes |
| Master fund | No |
| Feeder fund | No |
| Fund of funds | No |
| Relies on exemption from registration | Yes |
| Annual audit | Yes |
| Prepared per GAAP | Yes |
| Sub-advised | No |
| % of assets independently valued | 100% |
| Owned by the adviser or related persons | 6% |
| Owned by funds of funds | 38% |
| Owned by non-U.S. persons | 26% |
| Fund | Type | Gross assets |
|---|---|---|
| Novaquest Pharma Opportunities Fund V, L.P. | Private Equity | $630.8M |
| Novaquest Pharma Opportunities Fund V (delaware), L.P. | Private Equity | $386.7M |
| Nq Project Pharaoh, L.P. | Private Equity | $138M |
Novaquest Pharma Opportunities Fund IV, L.P. reports $158.1 million in gross assets, among the top 34% of private funds by size.
The stated minimum investment is $25 million.
Novaquest Pharma Opportunities Fund IV, L.P. is managed by Novaquest Capital Management, L.L.C.
No. Private funds are not required to publicly disclose performance. Form ADV reports assets, structure, and service providers.